Кто говорит, что ротация это плохо?
2018 starts with welcoming a new WGA President: Keith Martin, Professor and Head of Ophthalmology, University of Cambridge, UK. The new President Elect is Fabian Lerner, Professor of Ophthalmology, University Favaloro School of Medical Sciences in Buenos Aires, Argentina.
At the Executive Office we welcome Shan Lin, Professor of Clinical Ophthalmology at the University of California, San Francisco, US as Executive Vice President and Kaweh Mansouri, Consultant at the Glaucoma Center, Montchoisi Clinic, Lausanne, Switzerland as Associate Executive Vice President.
New members of the WGA Board of Governors per 2018 are Arthur Sit (Rochester, Minnesota United States), Ingeborg Stalmans (Leuven, Belgium), Fotis Topouzis (Thessaloniki, Greece) and Lingam Vijaya (Chennai, India).
When patients receive a new diagnosis of glaucoma, they suddenly face the numerous, complex trade-offs in risks and benefits posed by the three main options for therapy—medications, laser surgery, and incisional surgery. For a majority of patients, starting a topical glaucoma medication is the most intuitive first step of treatment. The practice of instilling eye drops may be familiar if they wear contact lenses or have administered topical ophthalmic solutions for dry eye disease or allergic conjunctivitis. Moreover, for many of them, daily medication use is already a part of their routine.
Clinical Minute distills a peer-reviewed study into what is relevant for practicing clinicians/surgeons in approximately one minute.
In the debut episode of this series, Neda Shamie, MD, outlines a recent paper by Iqbal Ike K. Ahmed, MD, FRCSC, on the Xen implant (Allergan). The paper offers surgical pearls and patient management protocols to ensure successful outcomes with this microinvasive glaucoma surgical device.
What is the advantage to you of publishing in Pharmacogenomics and Personalized Medicine?
It is an open access journal which means that your paper is available to anyone in the world to download for free directly from the Dove website.
Although Pharmacogenomics and Personalized Medicine receives many papers, unlike most traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish.
The time from submission to a decision being made on a paper can, in many journals, take some months and this is very frustrating for authors. Pharmacogenomics and Personalized Medicine has a quicker turnaround time than this. Generally peer review is complete within 4-7 weeks and the editor’s decision within 2-14 days of this. It is therefore very rare to have to wait more than 9 weeks for a final decision.
Many authors have found that our peer reviewer’s comments substantially add to their final papers.
Question What is the association of systemic medication with intraocular pressure in a multiethnic Asian population?
Findings In a post hoc analysis of a population-based study of 8063 participants from 3 ethnic groups (Chinese, Malays, and Indians), lower intraocular pressure was more likely associated with participants using systemic β-blockers, whereas higher intraocular pressure was more likely associated with participants using angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, statins, or sulfonylureas.
Meaning The effect of commonly dispensed systemic medication on intraocular pressure may have implications for glaucoma risk in individuals taking these medications for coexisting comorbidities.
ournal of Glaucoma is currently the only scientific journal devoted to glaucoma that is both indexed and has an impact factor, giving the Journal a unique position in the glaucoma community. In conjunction with the World Glaucoma Association, the publisher will be offering remarkably low rates for both hard copy and electronic subscriptions. More information about this will follow from the publisher and the WGA once details of the new relationship are finalised.
Abstract: Vernal keratoconjunctivitis (VKC) is a chronic allergic conjunctivitis that is most often seen in young, males. Although most types of allergic conjunctivitis do not affect vision, VKC is unusual in that damage to the cornea from the condition can result in vision loss. Although it is typically seasonal, year-round symptoms can be seen, which can lead to uncertain diagnoses being made. Although the pathophysiology of VKC is better understood in recent years, allowing more targeted therapies, management of these patients can still be very challenging, and complications can occur. As such, aggressive management of VKC is necessary, especially since vision loss in the amblyogenic age range can be permanent
Очередной выпуск журнала «Офтальмология» приурочен к международной конференции «Актуальные проблемы офтальмологии»,
посвященной 95-летнему юбилею академика Зарифы Алиевой.
Просим присылать статьи на электронный адрес firstname.lastname@example.org до 15.02.2018г.
Требования оформления статей размещены на сайте www.oftalmologiya.az
Редакция журнала «Офтальмология»
Ted Garway-Heath, as in-coming president, has big shoes to fill! The EGS goes from strength to strength in achieving its vision to promote the best possible well being and minimal glaucoma-induced visual disability in individuals with glaucoma within an affordable healthcare system. This would not be possible without the teamwork and friendship of many contributors
Twenty-five years old is a good age to be. Any older and your hearing starts to decline; the loss may be barely detectable at that stage – but it’s only going in one direction. By the start of your fourth decade, your bone and skeletal muscle mass starts to decline, and by your mid-forties, a number of ocular diseases start to manifest: incipient cataract, slight drusen deposits, a small raise in IOP... and presbyopia. Some people experience it in their forties, others in their fifties. It’s most definitely age-related, and for now, almost certainly inescapable
The International Council of Ophthalmology (ICO) Fellowships Program was organized to help promising young ophthalmologists from developing countries improve their practical skills and broaden their perspectives of ophthalmology. Fellows are expected to bring the acquired knowledge and skills back to their home countries and take part in programs to preserve vision and prevent blindness. For the ICO-Allergan Research Fellowship we encourage applicants from all countries.
The ICO gratefully recognizes grants, gifts, and pledges to the ICO Fellowships Program. Support ICO Fellowships by contributing to the ICO, ICOFoundation, or the International Ophthalmological Fellowship Foundation (IOFF). The IOFF was formed in Germany to support the fellowships. View ICO Fellowship donors.
Сайт основан 20 декабря 2000 года
Авторские права на дизайн и всю информацию веб-сайта www.eyenews.ru (www.glaucomanews.ru www.corneanews.ru, www.cataractanews.ruwww.retinanews.ru www.айньюс.рф www.hrtclubrussia.ru), а также на подбор и расположение материалов принадлежат учредителю и редакции вышеуказаных порталов. Использование материалов сайтов разрешено только с письменного разрешения учредителя и редакции вышеуказанных сайтов. Воспроизведение фотографий, статей и новостей, абстрактов и прочего контента любым способом без письменного разрешения запрещено и влечет ответственность, предусмотренную законодательством о защите авторских прав. Запрещается автоматизированное извлечение информации сайта любыми сервисами без официального разрешения учредителя либо редакции сайтов. При цитировании материалов ссылка наwww.eyenews.ru и другие вышеуказанные сайты обязательна.